Dr. Allen Davidoff, Ph.D.: President and CEO
Dr. Allen W. Davidoff, Ph.D. (10 years drug development ), Formerly, Chief Scientific officer, VP Product Development and co-founder of Stem Cell Therapeutics Corp. (7 yrs). Previous to Stem Cell Therapeutics Corp., Senior Scientist and Head of Pharmacology at Cardiome Pharma and has 10 years of drug development experience with a broad clinical and regulatory experience. Senior management experience in pharmaceutical R&D including 2 investigational new drug (“IND”) applications or supplemental IND’s, 2 phase I studies (4 multi-country), 7 phase II studies, and 1 NDA.
Grace Jung, PhD: Director of Chemistry and Manufacturing
Grace Jung, PhD (21 years of experience in drug discovery and development) was formerly Senior Director of Research (Chemistry) at Cardiome. During the 14 years at Cardiome, she led the chemistry team in the discovery of antiarrhythmic vernakalant and in process research efforts to devise a scalable manufacturing route for vernakalant. Before joining Cardiome, Grace spent 7 years at Boehringer Ingelheim (Laval, QC, Canada), where she was a medicinal chemist working on renin inhibitors as antihypertensive drugs.
Brian Mangal, MsC. BioStatistics: Director Business Development, Product Development
Brian Mangal, MsC. (12 years of clinical development experience) was formerly, Director of Biostatistics for Cardiome Pharma Corp, and responsible for all biometric activities related to the advancement of Cardiome’s clinical programs. Clinical development experience includes design, analysis and reporting on over 50 clinical trials, three FDA submissions, one TPD submission, a successful EMEA submission. Prior to Cardiome, worked on building a CRO – Everest Clinical Research, specializing in dealings with NIH in the US and as a Biostatistician at Pharmacia/Pfizer, worked on the successful sNDA for Linezolid and numerous successful trials with Celecoxib.
Dr. Alan Moore, Founding Board Member, Executive Consultant: Clinical and Regulatory Affairs
Dr. Alan F. Moore, Ph.D. Dr. Moore has extensive clinical development experience and 23 years of senior management experience in pharmaceutical R&D. During his esteemed career, he has completed 11 investigational new drug (“IND”) applications or supplemental IND’s, 15 phase I studies, 12 phase II studies, 7 phase III studies and 2 new drug applications. Most recently CEO of BetaStem Inc.